Why is a potential ‘wonder drug' for women's health still being overlooked one year after the Government's "Women's Health Strategy" was launched?
Z News Service
21 July 2023
The Women's Health Strategy for England Report, published in July 2022, acknowledged that the health of women and girls over the course of their lives has long been neglected.
Low-dose naltrexone (LDN) is being prescribed by some pharmacists and medical professionals, particularly in the United States, to help with symptoms such as memory loss, brain fog and mood swings. It helps by boosting natural endorphins, which the body produces to relieve pain and stress. However, it remains under-funded and under-supported, despite its potential to help so many women.
In the UK, there is a charity called The LDN Research Trust, which was created by Linda Elsegood after discovering LDN for treatment of her severe MS symptoms. She now runs the charity, and has just returned from hosting the 9th LDN Conference in America, something she would never have dreamed of doing before taking LDN when her MS was so severe she relied on a wheelchair to get around outside of the house. They work internationally and report that the use of LDN is spreading. The ultimate goal is for there to be greater awareness of, and access to, LDN for a wide range of conditions.
Low-dose naltrexone reduces pain and fights inflammation. It is used to treat cancers, mental health issues, autoimmune diseases, chronic pain and lots more. "I think it would benefit the government to explore the potential benefits of LDN as a treatment option for women’s health issues. LDN is known to be a safe, non-toxic, inexpensive drug. Utilising LDN could help millions of women in the UK improve their quality of life. Additionally, implementing LDN as a treatment option could save the government millions of pounds in the long run." – Linda Elsegood, The LDN Research Trust Founder